Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 7, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Cervical Cancer
Interventions
DRUG

Cadonilimab

The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment

Trial Locations (1)

350074

RECRUITING

No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province, Fuzhou

All Listed Sponsors
collaborator

Fujian Medical University Affiliated Nanping First Hospital

UNKNOWN

collaborator

The First Hospital Affiliated to Fujian Medical University

UNKNOWN

collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Gutian Hospital

UNKNOWN

collaborator

Jiangxi Provincial Cancer Hospital

OTHER

collaborator

Shunde Women and Children's Hospital (Maternity and Child Healthcare Hospital of Shunde Foshan)

UNKNOWN

collaborator

Lianyungang Donghai County People's Hospital

UNKNOWN

collaborator

Changsha Maternal and Child Health Hospital

UNKNOWN

collaborator

Pingxiang Maternal and Child Health Hospital

UNKNOWN

collaborator

Huinan County People's Hospital

UNKNOWN

collaborator

People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

UNKNOWN

lead

Fujian Cancer Hospital

OTHER_GOV